(Total Views: 519)
Posted On: 02/14/2020 8:40:18 PM
Post# of 153940
You have to admit, it looks way better now than your last expectation in the fall of going bankrupt.
For BLA, the FDA wanted all the safety data, then they will pick the 50 patients, which makes sense, to avoid handpicking data, especially given the great safety record of leronlimab compared to other ccr5 antagonists. With NP paying more for all the overtime the month to get that safety data in BLA format, I get the impression he is pushing hard for February, at least part 2. All, imo.
For BLA, the FDA wanted all the safety data, then they will pick the 50 patients, which makes sense, to avoid handpicking data, especially given the great safety record of leronlimab compared to other ccr5 antagonists. With NP paying more for all the overtime the month to get that safety data in BLA format, I get the impression he is pushing hard for February, at least part 2. All, imo.
(5)
(0)
